Myriad Genetics (MYGN) Cash from Investing Activities (2009 - 2026)
Myriad Genetics (MYGN) posted quarterly Cash from Investing Activities of -$6.5 million for Q1 2026, up 21.69% year-over-year from -$5.3 million in Q1 2025, and down 8.33% quarter-over-quarter from -$6.0 million in Q4 2025.
Myriad Genetics (MYGN) Cash from Investing Activities (2009 - 2026) Analysis & Trends
Myriad Genetics (MYGN) has reported Cash from Investing Activities for 18 consecutive years, with -$6.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 21.69% year-over-year to -$6.5 million; the TTM figure through Mar 2026 stood at -$25.6 million (down 95.42% YoY), while the FY2025 annual figure was -$27.4 million, down 130.25% from the prior year.
- Cash from Investing Activities eased to -$6.5 million in Q1 2026 per MYGN's latest filing, from -$6.0 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $34.6 million in Q1 2023 and bottomed at -$41.3 million in Q1 2022.
- Historically, Cash from Investing Activities has averaged -$5.4 million across 5 years, with a median of -$6.4 million in 2024.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities sank 1190.91% — and 2024, when it surged 400.0%.
- Myriad Genetics' Cash from Investing Activities stood at -$35.6 million in 2022, then soared by 66.29% to -$12.0 million in 2023, then surged by 50.83% to -$5.9 million in 2024, then slipped by 1.69% to -$6.0 million in 2025, then fell by 8.33% to -$6.5 million in 2026.
- Business Quant data shows MYGN's Cash from Investing Activities at -$6.5 million in Q1 2026, -$6.0 million in Q4 2025, and -$6.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | 164.00 Mn |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | -10.15 Bn |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | -25.50 Mn |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | -77.00 Mn |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | -381.00 Mn |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | -32.14 Mn |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | -122.00 Mn |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | -1.94 Mn |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | -134.00 Mn |
| 10 | Myriad Genetics | 297.97 Mn | 173.57 Mn | 137.60 Mn | -6.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.50 Mn |
| Mar 31, 2026 | -6.50 Mn |
| Dec 31, 2025 | -6.00 Mn |
| Dec 31, 2025 | -6.00 Mn |
| Sep 30, 2025 | -6.20 Mn |
| Sep 30, 2025 | -6.20 Mn |
| Jun 30, 2025 | -6.90 Mn |
| Jun 30, 2025 | -6.90 Mn |
| Mar 31, 2025 | -8.30 Mn |
| Mar 31, 2025 | -8.30 Mn |
| Dec 31, 2024 | -5.90 Mn |
| Dec 31, 2024 | -5.90 Mn |
| Sep 30, 2024 | 7.50 Mn |
| Sep 30, 2024 | 7.50 Mn |
| Jun 30, 2024 | -6.40 Mn |
| Jun 30, 2024 | -6.40 Mn |
| Mar 31, 2024 | -7.10 Mn |
| Mar 31, 2024 | -7.10 Mn |
| Dec 31, 2023 | -12.00 Mn |
| Dec 31, 2023 | -12.00 Mn |